AU2707797A - Methods and means for inhibition of cdk4 activity - Google Patents
Methods and means for inhibition of cdk4 activityInfo
- Publication number
- AU2707797A AU2707797A AU27077/97A AU2707797A AU2707797A AU 2707797 A AU2707797 A AU 2707797A AU 27077/97 A AU27077/97 A AU 27077/97A AU 2707797 A AU2707797 A AU 2707797A AU 2707797 A AU2707797 A AU 2707797A
- Authority
- AU
- Australia
- Prior art keywords
- cdk4
- activity
- inhibition
- methods
- sup
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000000694 effects Effects 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 2
- 101100005789 Caenorhabditis elegans cdk-4 gene Proteins 0.000 title 1
- 230000005764 inhibitory process Effects 0.000 title 1
- 102000013701 Cyclin-Dependent Kinase 4 Human genes 0.000 abstract 4
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 abstract 4
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 102000006311 Cyclin D1 Human genes 0.000 abstract 1
- 108010058546 Cyclin D1 Proteins 0.000 abstract 1
- 102100033270 Cyclin-dependent kinase inhibitor 1 Human genes 0.000 abstract 1
- 101000944380 Homo sapiens Cyclin-dependent kinase inhibitor 1 Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102000007079 Peptide Fragments Human genes 0.000 abstract 1
- 108010033276 Peptide Fragments Proteins 0.000 abstract 1
- 238000003556 assay Methods 0.000 abstract 1
- 230000004663 cell proliferation Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000003463 hyperproliferative effect Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000003993 interaction Effects 0.000 abstract 1
- 125000001151 peptidyl group Chemical group 0.000 abstract 1
- 230000026731 phosphorylation Effects 0.000 abstract 1
- 238000006366 phosphorylation reaction Methods 0.000 abstract 1
- 238000012216 screening Methods 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9609521.1A GB9609521D0 (en) | 1996-05-08 | 1996-05-08 | Substances and their therapeutic use |
| GB9609521 | 1996-05-08 | ||
| GB9621314 | 1996-10-09 | ||
| GBGB9621314.5A GB9621314D0 (en) | 1996-10-09 | 1996-10-09 | Substances and their therapeutic use |
| PCT/GB1997/001250 WO1997042222A1 (en) | 1996-05-08 | 1997-05-08 | Methods and means for inhibition of cdk4 activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2707797A true AU2707797A (en) | 1997-11-26 |
Family
ID=26309279
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU27077/97A Abandoned AU2707797A (en) | 1996-05-08 | 1997-05-08 | Methods and means for inhibition of cdk4 activity |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US6962792B1 (enExample) |
| EP (1) | EP0898580B9 (enExample) |
| JP (1) | JP4205165B2 (enExample) |
| AT (1) | ATE333465T1 (enExample) |
| AU (1) | AU2707797A (enExample) |
| DE (2) | DE69736351D1 (enExample) |
| WO (1) | WO1997042222A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997042222A1 (en) | 1996-05-08 | 1997-11-13 | Cyclacel Limited | Methods and means for inhibition of cdk4 activity |
| GB9727277D0 (en) * | 1997-12-23 | 1998-02-25 | Medical Res Council | Assay |
| WO1999042821A2 (en) * | 1998-02-18 | 1999-08-26 | Theryte Limited | Treating cancer |
| EP1338652A3 (en) * | 1998-03-23 | 2004-05-19 | E.I.Du pont de nemours and company | Plant cell cyclin genes |
| BR9907965A (pt) * | 1998-03-23 | 2000-12-12 | Du Pont | Fragmento de ácido nucléico isolado, gene quimérico, célula hospedeira transformada, polipetìdios, processo de alteração do nìvel de expressão de uma proteìna ciclina em uma célula hospedeira, método de obtenção de um fragmento de ácido nucleìco, produto e método de avaliação de pelo menos um composto quanto à sua capacidade de inibir a atividade de uma proteìna ciclina |
| WO2000038733A1 (en) * | 1998-12-24 | 2000-07-06 | Ucb S.A. | Peptidic product, process and composition |
| EP1165793A2 (en) * | 1999-04-07 | 2002-01-02 | E.I. Du Pont De Nemours And Company | Cyclin dependent kinase inhibitor genes from plants |
| US20050153894A1 (en) * | 1999-11-30 | 2005-07-14 | Cyclacel Limited | p21 peptides |
| GB9928323D0 (en) * | 1999-11-30 | 2000-01-26 | Cyclacel Ltd | Peptides |
| GB2369823B (en) * | 1999-11-30 | 2003-06-04 | Cyclacel Ltd | Assays for cyclin-interacting compounds |
| US7449544B2 (en) | 1999-11-30 | 2008-11-11 | Cyclacel Limited | p21 peptides |
| GB0012528D0 (en) * | 2000-05-23 | 2000-07-12 | Univ Palackeho | Triterpenoid derivatives |
| GB0030378D0 (en) | 2000-12-13 | 2001-01-24 | Cyclacel Ltd | Compound |
| AU2003258095A1 (en) * | 2002-08-07 | 2004-02-25 | Exelixis, Inc. | MP21S AS MODIFIERS OF THE p21 PATHWAY AND METHODS OF USE |
| GB0229151D0 (en) | 2002-12-13 | 2003-01-15 | St Georges Entpr Ltd | Product and method |
| WO2005040207A1 (en) * | 2003-10-20 | 2005-05-06 | F. Hoffmann-La Roche Ag | Tyrosine phosphorylation of cdk inhibitor proteins of the cip/kip family |
| JP5164380B2 (ja) * | 2003-10-21 | 2013-03-21 | サイクラセル リミテッド | ピリミジン−４−イル−３，４−チオン化合物及び治療におけるその使用 |
| GB0402653D0 (en) * | 2004-02-06 | 2004-03-10 | Cyclacel Ltd | Compounds |
| GB0411791D0 (en) * | 2004-05-26 | 2004-06-30 | Cyclacel Ltd | Compounds |
| ES2403558T3 (es) | 2004-08-27 | 2013-05-20 | Cyclacel Limited | Inhibidores purínicos y pirimidínicos de CDK y su uso para el tratamiento de enfermedades autoinmunitarias |
| US20090286738A1 (en) * | 2005-06-29 | 2009-11-19 | St. George's Enterprises Limited | Gene Regulation |
| EP2224961A1 (en) * | 2007-11-26 | 2010-09-08 | The Research Foundation of the State University of New York | Small molecule cancer treatments that cause necrosis in cancer cells but do not affect normal cells |
| US9040046B2 (en) | 2011-01-31 | 2015-05-26 | Kai Xu | Sodium pump antibody agonists and methods of treating heart disease using the same |
| CN112236162A (zh) | 2018-04-06 | 2021-01-15 | 昂科莱奇公司 | 用于裂解选择性癌细胞的组合物 |
| EP3849537B1 (en) | 2018-09-10 | 2024-10-23 | Mirati Therapeutics, Inc. | Combination therapies |
| CN118324906A (zh) * | 2024-06-14 | 2024-07-12 | 上海交通大学医学院附属上海儿童医学中心 | p21特异性修饰的抗体及制备方法和应用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2759164A1 (de) | 1977-12-31 | 1979-07-12 | Basf Ag | Photopolymerisierbare ueberzugs- und aufzeichnungsmaterialien, enthaltend einen photoinitiator und eine organische halogenverbindung |
| US5229018A (en) | 1986-02-24 | 1993-07-20 | Forrest Gabriel T | Completion and workover fluid for oil and gas wells comprising ground peanut hulls |
| FR2662698A1 (fr) * | 1990-06-05 | 1991-12-06 | Centre Nat Rech Scient | Nouveaux facteurs de croissance neurotropes comprenant un peptide homeoboite. |
| US5302706A (en) | 1991-12-16 | 1994-04-12 | Baylor College Of Medicine | Senescent cell derived inhibitors of DNA synthesis |
| US5596079A (en) | 1991-12-16 | 1997-01-21 | Smith; James R. | Mimetics of senescent cell derived inhibitors of DNA synthesis |
| CA2146965C (en) | 1992-10-16 | 2003-07-29 | David H. Beach | Cyclin complex rearrangement and uses related thereto |
| GB9305448D0 (en) | 1993-03-17 | 1993-05-05 | British Tech Group | Semiconductor structure and method of manufacturing same |
| CA2170641C (en) | 1993-08-30 | 2011-11-15 | James R. Smith | Senescent cell-derived inhibitors of dna synthesis |
| WO1995013375A1 (en) | 1993-11-10 | 1995-05-18 | The Johns Hopkins University | Tumor suppressor waf1 |
| DE69533804T2 (de) | 1994-05-24 | 2006-05-11 | Baylor College Of Medicine, Houston | Mimetika von aus alternden Zellen abgeleiteten Hemmern der DNA-Synthese |
| GB9422175D0 (en) | 1994-11-03 | 1994-12-21 | Univ Dundee | Indentification of the p21 waf1-pcna interaction site and therapeutic applications thereof |
| GB9509557D0 (en) | 1995-05-11 | 1995-07-05 | Univ Dundee | PCNA binding substance |
| CA2227370A1 (en) | 1995-07-20 | 1997-02-06 | Worcester Foundation For Biomedical Research, Inc. | Methods for selectively killing or inhibiting the growth of cells expressing the waf1 gene |
| US5672508A (en) | 1996-01-23 | 1997-09-30 | Mitotix, Inc. | Inhibitors of cell-cycle progression, and uses related thereto |
| WO1997042222A1 (en) | 1996-05-08 | 1997-11-13 | Cyclacel Limited | Methods and means for inhibition of cdk4 activity |
-
1997
- 1997-05-08 WO PCT/GB1997/001250 patent/WO1997042222A1/en not_active Ceased
- 1997-05-08 JP JP52963597A patent/JP4205165B2/ja not_active Expired - Fee Related
- 1997-05-08 US US09/180,269 patent/US6962792B1/en not_active Expired - Fee Related
- 1997-05-08 AU AU27077/97A patent/AU2707797A/en not_active Abandoned
- 1997-05-08 EP EP97920857A patent/EP0898580B9/en not_active Expired - Lifetime
- 1997-05-08 DE DE69736351A patent/DE69736351D1/de not_active Expired - Fee Related
- 1997-05-08 AT AT97920857T patent/ATE333465T1/de not_active IP Right Cessation
- 1997-05-08 DE DE69736351T patent/DE69736351T4/de not_active Expired - Lifetime
-
2003
- 2003-08-22 US US10/646,267 patent/US20040214765A1/en not_active Abandoned
-
2008
- 2008-06-04 US US12/133,242 patent/US20080249025A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO1997042222A1 (en) | 1997-11-13 |
| US20080249025A1 (en) | 2008-10-09 |
| DE69736351T2 (de) | 2007-07-12 |
| EP0898580A1 (en) | 1999-03-03 |
| ATE333465T1 (de) | 2006-08-15 |
| US6962792B1 (en) | 2005-11-08 |
| DE69736351T4 (de) | 2009-07-23 |
| EP0898580B1 (en) | 2006-07-19 |
| DE69736351D1 (de) | 2006-08-31 |
| EP0898580B3 (en) | 2008-10-29 |
| JP2000513805A (ja) | 2000-10-17 |
| US20040214765A1 (en) | 2004-10-28 |
| JP4205165B2 (ja) | 2009-01-07 |
| EP0898580B9 (en) | 2009-08-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2707797A (en) | Methods and means for inhibition of cdk4 activity | |
| AU3738397A (en) | 2-methoxyestradiol-induced apoptosis in cancer cells | |
| AU3847997A (en) | Inhibitors of the interaction between P53 and MDM2 | |
| IL117425A0 (en) | Receptor activation by gas6 | |
| AU1367095A (en) | Effector proteins of rapamycin | |
| WO2001031335A3 (en) | Cell proliferation diagnosis and screening for modulators | |
| WO1999006540A3 (en) | Inhibitors of cell-cycle progression and uses related thereto | |
| WO1998025598A3 (en) | Methods and pharmaceutical compositions for inhibiting tumour cell growth | |
| WO1996034113A3 (en) | Methods for the identification of farnesyltransferase inhibitors | |
| AU3801997A (en) | Assays for protein kinases using fluorescent protein substrates | |
| WO2001023412A3 (en) | Methods of screening for agents which inhibit aggregation of polypeptides | |
| AU7934900A (en) | Method of screening for inhibitors of asp2 | |
| AU5229498A (en) | Mutants of the lag-3 proteins, products for the expression of these mutants and use | |
| WO2004069200A3 (en) | Specific inhibitors of nfat activation by calcineurin and their use in treating immune-related diseases | |
| CA2265444A1 (en) | Tnf-beta-like protein for treating prostate cancer, and related nucleic acid molecules, pharmaceutical compositions and methods | |
| AU6865600A (en) | Cell proliferation inhibitory protein, polynucleotide, antisense polynucleotide to the polynucleotide, and cell proliferation inhibitors, cancer diagnostics, cancer remedies and compositions for gene therapy by using the same | |
| AU749763C (en) | Modification of cereal grain hardness via expression of puroindoline proteins | |
| WO2001004283A3 (en) | Organic anion transporter genes and proteins | |
| WO2000078795A3 (en) | Rufomycins and derivatives thereof useful as inhibitors of multi-drug resistance associated protein-1 (mrp-1) | |
| AU7525398A (en) | Inhibitors for urokinase receptor | |
| AU1559501A (en) | Apoptosis inducing proteinaceous substance | |
| WO2004075839A3 (en) | Methods and compositions for modulating apoptosis | |
| ATE362768T1 (de) | Prb2/p130 peptidinhibitoren der cdk2 kinaseaktivität | |
| WO2004043371A3 (en) | Methods and compositions for modulating p53 transcription factor | |
| AU3880900A (en) | Surface localized colligin/hsp47 in carcinoma cells |